extract [hPTH-(TCA) [3583][3584][3585][3586][3587][3588]. Inhibition studies were also carried out with bPTH-( 1-34) and bPTH-(1-84). Anti-hPTH-(TCA) exhibited specificities directed to determinants in the COOH-terminal and NH2-terminal part of hPTH-(1-84) and exhibited cross-reactivity with bPTH-(1-84).
A B S T R A C T Antibodies to a urea-trichloroacetic acid extract [hPTH-(TCA)] of human parathyroid tumors and to the synthetic NH2-terminal fragments of human parathyroid hormone hPTH-(1-12) and - were developed in goats to characterize immunochemically various PTH preparations and to estimate immunoreactive PTH (iPTH) in human sera. They were quantitated on the basis of their capacity to bind [9I]-hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , [1I] hPTH- or ["lI]bovine PTH (bPTH- ). The quality of the antibodies was assessed by reference to inhibition of their interaction with labeled peptides by synthetic hPTH comprising 34 NH2-terminal amino acid residues or fragments thereof [hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , - , - (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , - (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , - (18) (19) (20) (21) (22) (23) (24) ] or by the Sephadex G-100-purified fulllength peptide hPTH- [hPTH-(1-84) G-100]. The synthetic peptides used in this work correspond in their structure to the NH2-terminal amino acid sequence 1-34, as elucidated by Brewer [3583] [3584] [3585] [3586] [3587] [3588] . Inhibition studies were also carried out with bPTH-( 1-34) and bPTH-(1-84). Anti-hPTH- (TCA) exhibited specificities directed to determinants in the COOH-terminal and NH2-terminal part of hPTH-(1-84) and exhibited cross-reactivity with bPTH-(1-84).
Anti-hPTH-(1-34), on the other hand, showed immunological specificities mainly directed to antigenic determinants located in the COOH-terminal half of
INTRODUCTION
Immunoreactive parathyroid hormone (iPTH)1 in man has been estimated by competitive binding technics using 1 Abbreviations used in this paper: B/F, ratio of antibody-bound [l12I]PTH and free [I] PTH; bPTH, bovine parathyroid hormone; dilution-50, serum dilution giving 50% binding of the labeled peptides; EGTA, ethylene glycolbis (P-aminoethyl ether) -N,N'-tetraacetic acid; hPTH, human parathyroid hormone; hPTH-(1-84) G-100, hPTH-(TCA) additionally gel filtrated through Sephadex G-100; hPTH-(TCA), a urea-trichloroacetic acid extract of human parathyroid tumors; ID., inhibition dose-50, amount of inhibitor required for a 50% reduction of specific binding of trace-labeled antigen to antibody; iPTH, immunoreactive parathyroid hormone; pPTH, porcine PTH.
exclusively heterologous systems (1) (2) (3) (4) (5) (6) (7) (8) . These radioimmunoassays are based on the ability of human iPTH to compete with radiolabeled bovine PTH (bPTH) for binding to an antiserum raised against bPTH or porcine PTH (pPTH). The estimation of iPTH in human serum is problematic mainly for two reasons. Apart from structural differences between PTH's originating from several species and the varying degree of immunological cross-reactivity between these peptides and human PTH (hPTH), the main obstacle to the measurement of absolute concentrations of the hormone is the presence in the circulation of PTH peptides of different molecular weight that react with antisera to PTH differently. The immunological heterogeneity of iPTH in human plasma was first demonstrated by Berson and Yalow (9) , and a similar dissociation in immunoreactivity between serum and glandular PTH was de- scribed by Arnaud, Tsao, and Oldham (10) . The concept suggesting the presence of more than one molecular-weight species of PTH in the circulation was subsequently confirmed (11) (12) (13) (14) . Since then, many attempts have been made to determine the immunochemical properties of PTH obtained from man (15) (16) (17) (18) (19) .
Recently, hPTH was isolated from parathyroid tumors. Its NH2-terminal amino acid sequence (residues 1-34) was determined by Brewer, Fairwell, Ronan, Sizemore, and Arnaud (20) , and the biologically active (21, 22) hPTH-(1-34) was synthesized by Andreatta et al. (22) . Subsequently, we gave a preliminary account of the immunochemical properties of the synthetic NH2-terminal PTH fragment (23) . Most recently, Niall et al. (24) reported for hPTH a NH2-terminal amino acid sequence comprising residues 1-37 which differs at three positions from the sequence reported by Brewer and co-workers (20) . The reason for this discrepancy is not yet clear. One possibility is that there are several isohormones of hPTH, as suggested by the results of O'Riordan et al. (25) . The 1-34 sequence of Niall et al. (24) was also synthesized (26) .
In the present investigation, antisera to a urea-trichloroacetic acid extract of human parathyroid tumors as well as to synthetic fragments hPTH-(1-12) and -(1-34) (22) based on the structure of Brewer et al. (20) have been studied and their immunological specificity has been analyzed. In addition, it has been shown that some of these antibodies are useful for quantitating iPTH levels in the sera of patients exhibiting primary hyperparathyroidism as well as in sera of control subjects.
METHODS
Peptides. A urea-trichloroacetic acid extract [hPTH-(TCA)] (27) of human parathyroid tumors (kindly provided by the European PTH Study Group) was prepared EFFLUENT VOLUME (ml) FIGURE 'Whenever hPTH-(1-84)G-100 is used in the present context, the actual amount of hPTH-(1-84) is calculated. (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and NasI were added (flow rates 1.4-1.6 ml/h, 0.7-0.8-ml fractions). Radioactivity was determined in an automatic gamma-well spectrometer (Nuclear-Chicago Corp., Des Plaines, Ill.). The amount of each labeled peptide marker was kept low enough not to interfere with radioimmunological determinations.
Trace-labeling of peptides. Synthetic hPTH-(1-12), -(1-34), and purified bPTH-(1-84) (the latter being chosen instead of highly purified hPTH-(1-84) which was not available in sufficient quantities) were radioiodinated by a modified Hunter and Greenwood chloramine-T procedure (28) as described by Berson and Yalow (29) . NaI was obtained from The Radiochemical Centre, Amersham, England and used on the day of arrival. The specific activities of [mI]hPTH-(1-12), -(1-34), and ['I]bPTH- (144) were estimated to range between 130-220 mCi/mg, 150-300 mCi/mg, and 200-500 mCi/mg, respectively, and were assessed by chromatoelectrophoresis (30) carried out at room temperature (Fig. 1) . In the absence of tyrosine residues in hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Table I ) and diluted 1:400. Ordinate: percent initial B/F (without inhibitor added). Inhibitors:
(Reeve Angel, London, England) (30) , and [.3 .I]hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) was purified on Bio-Gel P-6 columns as described above. Fig. 1 (25-30 kg) . Simultaneously, 0.5 ml of a Bordetella pertussis vaccine (4x 10"l B. pertussis phase I organisms per ml, Swiss Institute of Sera and Vaccines, Berne, Switzerland) was administered subcutaneously at a single site. Blood samples were obtained from the jugular vein and allowed to clot at room temperature. The sera were heat inactivated (560C, 30 min) and stored in small portions at -20'C until use.
Antibodies were quantitated on the basis of their capacity to bind trace-labeled antigen. The incubation volume was 0.5 ml containing about 15,000 cpm of trace-labeled hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Qualitative properties of antibodies and radioimmunoassay of iPTH in human sera. Inhibition by various PTH preparations of the primary interaction between antibodies and trace-labeled peptides was determined with dilutions of antisera yielding 30-40% specific binding in the absence of inhibitor. Graded amounts of inhibitors were preincubated for 3-4 days at 4VC (total volume 0.3 ml). Then 0.2 ml diluent containing the trace-labeled peptide was added, and the mixture was incubated for another 3 days. The amount of radioactivity specifically bound to antibody in the presence of inhibitors was compared with the control to which no inhibitor had been added. Each standard or unknown B/F ratio is expressed as a percentage of the initial B/F ratio. The amounts of inhibitor required to reduce specific binding to 50% (ID50) were determined from graphs such as shown in Fig. 4 Undiluted or diluted sera in quantities of 0.2, 0.1, and 0.05 ml were added to the incubation system (total volume 0.5 ml). Control tubes with no antiserum containing 0.2 or 0.1 ml of the unknown serum served to correct for nonspecific "binding." In addition, control tubes in quadruplicate with and without antiserum containing 0.2, 0.1, and 0.05 ml serum obtained from patients with hypoparathyroidism after thyroidectomy were included in every assay. On no occasion did this control serum influence the B/F ratios. Intra-assay and interassay coefficients of variation amounted to 7 and 12%, respectively. Coefficients of variation were calculated according to Diem and Lentner (33) . RESULTS Antibodies to extracted hPTH. As shown in Table  I (Fig. 2, left panel) . The results were different when ["31I]bPTH-(1-84) was used as the labeled ligand. As shown in Table II and Fig. 2 (right panel) , synthetic hPTH-(1-34) in quantities as high as 5 iug had no inhibitory effect in this system. The extractive 1-84-peptide of both species exhibited similar inhibition patterns, but bPTH-(1-84) was a somewhat more potent inhibitor than hPTH-(1-84) G-100 and hPTH-(TCA).
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As assessed with ['1I]bPTH-(1-84) and anti-hPTH-(TCA) with hPTH-(1-84)G-100 as standard, the purity of extracted hPTH-(TCA) was estimated to range between 1.0 and 1.1% (Table III) .
Antibodies to synthetic NHs-terminat fragment -(1-12) of hPTH. Antibody activity in sera from goats immunized with hPTH-(1-12) was rather low after the primary injection. As shown in Table IV , only two goats receiving 330 Ag of antigen had circulating antibodies in their sera when sampled on day 56. 9 days after a second injection of antigen, sera from two animals of the same group exhibited reciprocal dilution-50 values of 60 and 400. None of the sera from goats injected with 40 ug of the peptide on days 0 and 107 bound 50% of trace-labeled hPTH-(1-12) at dilutions as low as 1: 10. Inhibition doses-50 were determined on only a few occasions and were rather high, except in the case of antiserum from goat 8 (day 116). obtained from goat 8, day 116, (see Table V ) and diluted 1:1,500. Ordinate: percent initial B/F (without inhibitor added). Inhibitors: hPTH-(1-12) (*), hPTH-(1-34) (0), hPTH-(1-84)G-100 (V). The quantitative and qualitative properties of antihPTH-(1-12) from goat 8 (day 116) were assessed at various pH levels, since pH may alter the immunological interactions of peptides with their antibodies by changing conformational properties (21, 34, 35) . Dilution-50 was lowest at pH 5 and was found to be increased by a factor of approximately 1.6 at pH 6.2-8.6.
On the other hand, the ID50 of hPTH-(1-12) decreased by a factor of 2.9 when the pH was raised from 5.0 to 8.6 (Table V, first line). The inhibition patterns obtained with the homologous peptide hPTH-(1-12) and with hPTH-(1-34) and hPTH-(1-84) are shown in Fig. 3 . The differences seen at pH levels of 8.6 and 5.0 can also be expressed in terms of relative molar inhibition. Thus, the IDMm's of hPTH-(1-34) and -(1-84) relative to hPTH-(1-12) are 2.9 (at pH 8.6) and 16.6 (at pH 5.0) and 11.5 (at pH 8.6) and 18.3 (at pH 5.0), respectively.
Antibodies to synthetic NHx-terminal fragment -(1-34) of hPTH. In a previous publication, we described the immune response to hPTH-(1-34) in goats and demonstrated that high-titer antibodies in sera were obtained as early as 26 days after primary immunization (23) . As judged by IDM0 determinations, some of these antisera already had a rather strong affinity for the antigen. By day 116, 4 days after a second injection of hPTH-(1-34), sera from all the six goats immunized exhibited IDMo values of approximately 30 pg, indicating that every antiserum was potentially utilizable for estimating NH2-terminal PTH activity radioimmunologically in unknown samples. In the present study, we investigated additional qualitative properties of two of these antisera. Fig. 4 shows the immunological specificity of the day-26 serum from goat 10. As judged by the 1DM values read from the graph, the COOHterminal fragments -(13-34) and -(18-34) inhibited the primary interaction of ['I]hPTH-(1-34) with its antibody at concentrations approximately 10 times higher than the homologous inhibitor. On the other hand, a 50% inhibition by the NH2-terminal fragment - (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) and the shortest COOH-terminal fragment tested, - (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , was only obtained at concentrations 1,000 times higher than those of hPTH-(1-34). The intermediary fragment - (18) (19) (20) (21) (22) (23) (24) did not inhibit at all, whereas full-length human extracted peptide had an IDM approximately 30 times higher than IDMo of the homologous inhibitor. bPTH-(1-34) displayed an inhibition pattern similar to that of the COOH-terminal hPTH- (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , whereas the full-length peptide bPTH-(1-84) showed somewhat less inhibitory activity.
The inhibition patterns of hPTH-(1-34) and -(1-12) were similar, whereas those of the other inhibitors were different. This is also shown on Fig. 5 , which shows the qualitative properties of day-26 antiserum from goat 11. It can be seen that the inhibition curves of hPTH-(1-34) and - (1-12) (Fig. 7C) . On gel filtration of six hyperparathyroid sera, iPTH always eluted as a single peak between hPTH-(1-84) and -(1-34) (Fig. 8) . Nevertheless, the inhibition curves of hyperparathyroid sera and the gel filtration peak fractions of these and hPTH-(1-84)G-100 were superimposable, indicating immunological similarity (Fig. 9A) .
iPTH was also estimated with [mI]hPTH-(1-34), anti-hPTH-(1-34) and hPTH-(1-34) as standard and found to be measurable in every serum tested of 17 patients with primary hyperparathyroidism and in sera of 14 control subjects; iPTH was below the sensitivity of the assay (0.014 ng/ml) in sera from five additional control subjects. The mean iPTH levels were higher in patients with primary hyperparathyroidism than in control subjects. However, there was a large overlap between the two groups (Fig. 7D) . Again, the inhibition curves of hyperparathyroid sera and hPTH-(1-34) were superimposable, indicating immunological similarity (Fig. 9B) . On gel filtration (Fig. 8) , three peaks could be distinguished; the first eluted shortly after the void volume and the second co-eluted with hPTH-(1-84), whereas the third was located in the hPTH-(1-34) region. A comparable pattern was observed as regards the first and second peaks in five additional gel-filtrated sera from patients with primary hyperparathyroidism, whereas a variable amount of immunoreactivity was recognized in later eluting fractions; the third peak sometimes trailed into the [1"I]-hPTH- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) region. DISCUSSION Our present study was prompted by the availability of extracted hPTH in sufficiently large amounts and the availability of synthetic NH2-terminal fragments of hPTH comprising the first 34 amino acid residue and fragments thereof. For the first time, it was thus feasible to examine quantitatively and qualitatively the immune response of hPTH in animals and to use antibodies against the human hormone for estimating iPTH in sera obtained from patients suffering from primary hyperparathyroidism or in sera from normal subjects.
Antibodies to hPTH were induced in the goat, which has recently been shown to be very suitable for the production of large quantities of potent antibodies against 
Ko
EFFLUENT VOLUME (ml) FIGURE nated between the full-length human and bovine hormones.
The NH2-terminal dodecapeptide of hPTH, whose structure is undisputed and has been identically defined by two independent groups of workers (20, 24) , was chosen to produce antibodies which would make it possible to estimate the short-lived NH2-terminal PTH fragments claimed to be present in human sera (17) (18) (19) . In spite of the fact that the quantity and quality of the antibodies obtained against synthetic hPTH- (1-12) did not yet meet the prerequisites for a sensitive radioimmunoassay, it is felt that this system will be improved and will be useful for future clinical studies. (1) . These authors noted a considerable overlap between the iPTH levels in plasma from hyperparathyroid and normal subjects. In addition, in 20% of the plasma specimens hPTH-(1-34)) were in marked contrast. As compared with those found in the first assay system described above, the iPTH levels in the sera of normal and hyperparathyroid subjects largely overlapped. This finding parallels results obtained with anti-bPTH, exhibiting specificities primarily directed against NH2-terminal parts of the full-length PTH peptide (18, 19, 36) . It thus appears that the radioimmunological diagnosis of hyperparathyroidism can best be made by employing antibodies directed to COOH-terminal parts of hPTH-(1-84), thus confirming the findings of Arnaud, Goldsmith, Bordier, and Sizemore (19) . A great obstacle in quantitating iPTH in human sera is the presence of PTH peptides with different molecular weights (13) (14) (15) (16) (17) (18) (19) . Upon gel filtration of the incubation media of cultured explants of parathyroid adenomas, iPTH species with molecular weights ranging from 5,000 to greater than 10,000 daltons were observed (11, 12) . Analysis by gel chromatography of hyperparathyroid sera showed that the major species of iPTH in venous effluents from parathyroid adenomas represented glandular hPTH-(1-84), whereas the major species of iPTH in the peripheral circulation had a molecular weight of approximately 7,000 (13) and lacked NH2-terminal parts of the hPTH-(1-84) molecule (15, 16, 18, 19) . This would explain why the [KI]hPTH-(1-34), anti-hPTH-(1-34) system is not suitable for the estimation of iPTH in hyperparathyroid sera. Canterbury and Reiss (14) detected three molecular-weight classes of PTH in sera of hyperparathyroid patients. Besides components with molecular weights of 9,500 and 7,000-7,500, the authors described a class of iPTH having a molecular weight of 4,500-5,000. It is interesting to note that iPTH with molecular weight lower than 6,000 were mainly recognizable with antibodies to bPTH exhibiting NHs-terminal specificities (17) (18) (19) 36) . These results are confirmed and extended by the data we obtained by using antibodies to synthetic hPTH- to analyze gel filtration eluates from hyperparathyroid sera. The findings are consistent with the presence of biologically active NH.-terminal fragments in the circulation as demonstrated by Canterbury, Levey, and Reiss (37) . Our findings are furthermore consistent with the possibility that certain adenomas of the parathyroid secrete an iPTH which has a larger molecular weight than hPTH-(1-84) (12, 38) . The existence of precursor(s) of hPTH-(1-84) has been recently reported (39, 40) .
